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Objective: to study whether smoking and impaired pulmonary function are associated with the expansion of abdominal
aortic aneurysms (AAA).
Methods and material: seventy-nine men with small (3–5 cm), screen-detected AAA underwent a simple 5-step smoking
history, measurement of the forced first second expiratory volume (FEV1), venepuncture and annual ultrasound scan for
mean follow-up period of 3.5 years.
Results: all but one patient had a significantly reduced FEV1 (p , 0.05, Mann–Whitney). The FEV1/expected FEV1 ratio
(rFEV1) was not related to AAA expansion but was negatively correlated with P-elastase-a1-antitrypsin-complexes
(P-Elastase). P-Elastase was positively correlated with smoking and S-cotinine. Smoking, S-cotinine, and P-elastase were
positively correlated with the mean annual AAA expansion rate but not rFEV1.
Conclusion: in general, patients with AAA have impaired pulmonary function. A simple five step smoking classification is
as predictive of AAA-expansion as S-cotinine. Smoking may cause elastase secretion leading to pulmonary and aortic elastin
degradation but the lack of association between AAA-expansion and rFEV1 suggest that other mechanisms are important.
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Introduction
Patients with chronic obstructive pulmonary disease
(COPD) are more likely to have abdominal aortic
aneurysms (AAA) and AAA in such patients may be
more prone to rupture.1 – 12 The link may be related to
the degradation of elastic tissue by elastase in the
lungs and the aorta as a result of smoking.13 – 22
Specifically, smoking inhibits a1-antitrypsin, the
major inhibitor of elastase, and stimulates elastase
secretion from the neutrophils. The U.K. small
aneurysm trial showed a relationship between
decreasing FEV1 and AAA rupture23 and smoking is
clearly associated with the development,6,9,11,24,25 and
possibly the expansion and rupture, of AAA.26,27 The
aim of the present study was to examine the
relationship between smoking history, serum markers
of nicotine consumption (cotinine),28 lung function,
serum markers of elastolysis and AAA expansion in a
series of patients with small, screen-detected AAA.
Material and Method
The Viborg country AAA screening programme has
been described previously.7 Seventy-nine of all 110
small (3–5 cm), screen-detected AAA in 1994, who
attended at least one annual control scanning were
randomly selected to undergo a simple 5-step smoking
history, measurement of the forced first second
expiratory volume (FEV1),29 venepuncture and annual
ultrasound scan for mean follow-up of 3.5 years. The
relative FEV1 (rFEV1) was defined as actual FEV1/
predicted FEV1.30 The mean annual expansion was
calculated as: ((Present anteriorposterior (AP)-diam-
eter—Initial AP-diameter)/days of obser-
vation)*365.25 days. The two observers31 were blind
to the results from the blood-samples. S-a1-antitryp-
sin, P-elastase–a1-antitrypsin-complexes (P-Elastase)
(non-commercial ELISA), and S-Cotinine (RIA, Diag-
nostic Products Corp., LA, U.S.A.) were determined by
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standard methods as previously described.18,32,33
Smoking habits were classified as: 0 ¼ never or former
smokers, 1 ¼ 1–10 cigarettes daily, 2 ¼ 11–20 ciga-
rettes daily, 3 ¼ above 20 cigarettes daily. All others,
e.g., smokers with a mixed consumption of pipe,
cigars, and cigarettes, were ranked 4 based empirically
upon the median cotinine levels. The trial was
approved by the local scientific ethics committee and
reported to the Central Control of Registers. SPSS 10.0
was used for non parametric tests, Spearman’s
correlation, Mann–Whitney, and Kruskal–Wallis.34
Results
Demographic data of the selected and unselected cases
are presented in Table 1 showing no apparent
differences. The median annual AAA expansion was
2.3 mm, FEV1 was 2.25 (interquartile range [IQR]
1.56–2.88), and the rFEV1 was 0.70 (IQR 0.46–0.93).
All of the patients bar one had a FEV1 significantly
below expected (p , 0:05; Mann – Whitney). The
smoking scale correlated significant positively with
S-Cotinine, P-Elastase, S-a1-antitrypsine, and expan-
sion rate but not with rFEV1 (Table 2). S-Cotinine also
correlated with P-Elastase, S-a1-antitrypsin, and
expansion rate (Fig. 1) but not with rFEV1 (Table 3).
P-Elastase also correlated negatively with rFEV1,
positively with expansion rate (Fig. 2) and S-a1-
antitrypsin (Table 3). Finally, rFEV1 and mean annual
expansion rate did not correlate (r ¼ 0:13, p ¼ 0:26)
(Table 3, Fig. 3).
Discussion
All patients bar one had impaired lung function.30 The
Table 1. Medians and interquartiles of the various analysed parameters among those selected for the study and those who were not
selected to the study.
Selected study group n ¼ 79 Non-selected group n ¼ 31 p-value
25th Quartiles Median 75th Quartiles 25th Quartiles Median 75th Quartiles
Age (years) 67 69 71 66 68 70 0.15
AAA-size (mm) 31 33 39 30 32 38 0.40
Expansion rate (mm/year) 0.93 2.34 3.83 0.54 2.23 5.48 0.87
Systolic BP (mmHg) 140 160 170 150 160 175 0.38
Diastolic BP (mmHg) 85 90 100 90 100 100 0.43
ABI* (per cent) 81 100 114 85 100 116 0.52
rFEV1 (per cent) 52.0 72.5 91.5 53.0 77.0 86.0 0.96
Smokers (per cent) 37.5 39.2 0.87
p-values from a non-parametric comparison of these two subgroups are shown in the right column.
*ABI ¼ Ankle brachial blood pressure index.
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Fig. 1. Scatter plot of serum level of S-Cotinine and the
expansion rate of small abdominal aortic aneurysms.
Spearman’s correlation coefficient r ¼ 0:24 ðp ¼ 0:04Þ.
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Fig. 2. Scatter plot of plasma level of P-Elastase and the
expansion rate of small abdominal aortic aneurysms.
Spearman’s correlation coefficient r ¼ 0:30 ðp ¼ 0:0004Þ.
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negative correlation between FEV1 and P-Elastase
suggest that this is, at least partly, caused by
elastolysis. Similarly, the correlation between P-Elas-
tase and expansion implicates elastolysis in aneur-
ismal degradation. Perhaps surprisingly, therefore,
there was no correlation between FEV1 and expansion.
This may be because elastase plays a major role in the
pulmonary disease but only a small role in AAA,
where other proteases such as plasmin, metallo-
proteinases, and cysteine protheases are also
active.35 – 40
As cotinine has a half-life of about 18 h (cf. 2 h for
nicotine), plasma levels are constant during the
smoking hours. As urinary continue needs to be
creatinine-adjusted the measurement of plasma coti-
nine is preferable.41 – 44 The simple 5-step smoking
history obtained at interview was just as closely
associated with AAA expansion as P-Cotinine levels,
FEV1, P-Elastase, and S-a1-antitrypsin levels. This re-
affirms the importance of implementing effective
smoking cessation strategies in this patient
population.
To summarise, most men with AAA have impaired
pulmonary function. Smoking and elastase-secretion
are predictive for pulmonary and aortic elastin
degradation but the lack of association between
AAA-expansion and FEV1 suggests that additional
mechanisms are at work in the matrix degradation of
the aorta causing AAA.Ta
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Fig. 3. Scatter plot of the relative pulmonary function and the
expansion rate of small abdominal aortic aneurysms.
Spearman’s correlation coefficient r ¼ 0:13 ðp ¼ 0:26Þ.
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